Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a daily probiotic boost your brain?

NCT ID NCT07168824

Symptom relief Sponsor: Chi-Chang Huang Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a probiotic called PS23 can improve thinking and quality of life in people aged 50-85 who feel their memory is slipping but don't have dementia. Forty participants will take one capsule daily for 12 weeks, and researchers will measure changes in computer-based thinking tests and blood markers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lacticaseibacillus paracasei PS23 (a probiotic)
What this could lead to
If it works, this could point toward a simple, safe supplement to help with early memory or thinking problems.
What could go wrong
This is a small, early-stage trial with no placebo group, so results may be unreliable. The effect on cognition may be minimal or absent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 50 to 85 years who self-report experiencing signs of cognitive decline. * No prior diagnosis of dementia or Alzheimer's disease (AD). * Willing and able to comply with study assessments and requirements, and provide written informed consent. Exclusion Criteria: * Use of antibiotics or probiotic powder, capsules, or tablets within the past month. * Currently undergoing antibiotic treatment. * Known allergy to dairy products. * Presence of immunodeficiency or impaired immune function. * Diagnosis of small intestinal bacterial overgrowth (SIBO). * Determined unsuitable by the investigator, for example, initiation of any new medication or therapy during the study period, particularly those related to memory impairment or cognitive decline.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Subjective cognitive decline (SCD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction subjective cognitive decline

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Subjective cognitive decline (SCD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Graduate Institute of Sports Science, National Taiwan Sport University

    Taoyuan, 33301, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.